Popular Pre-Market Trades in U.S. Stocks
Larimar Therapeutics is down 8.40% in pre-market trading. Based on recent news,
<ol>
<li>
On February 24, the U.S. FDA granted breakthrough therapy designation to Larimar Therapeutics' experimental therapy nomlabofusp, leading to a 32% increase in stock price during pre-market trading. This designation aims to expedite the development and review of drugs for serious diseases or unmet medical needs.
</li>
<li>
On February 25, Larimar Therapeutics announced the pricing of a $100 million public offering, priced at $5.00 per share. The offering is expected to be completed on February 27, resulting in a 5.4% decline in stock price during after-hours trading.
</li>
<li>
On February 26, Larimar Therapeutics announced a $75 million fundraising plan, including stock and pre-funded warrants. The company plans to use the net proceeds to support the development of nomlabofusp as well as for working capital and general corporate purposes, including R&amp;D and commercialization expenses. The biotechnology sector has been volatile recently, and investors should exercise caution.
</li>
</ol>
Rich Sparkle is down 8.12% in pre-market trading. Based on recent news,
<ol>
<li>
On February 25, San Zhi Yang successfully backdoor listed Rich Sparkle on NASDAQ. Rich Sparkle acquired 100% of Step Distinctive, which is 13% owned by Anhui Xiao Hei Yang Network Technology under San Zhi Yang. This news attracted market attention, leading to stock price fluctuations.
</li>
<li>
On February 25, San Zhi Yang, through this transaction, collaborated with the globally popular Wu Yu Ge for exclusive global operating rights for 36 months, leveraging Rich Sparkle Holdings' NASDAQ listing platform to achieve &#34;backdoor listing overseas.&#34; This collaboration raised market concerns about future performance, leading to a decline in stock price.
</li>
<li>
On February 26, a press release from Rich Sparkle indicated that over the next 36 months, Rich Sparkle will partner with affiliated companies of San Zhi Yang Group to hold exclusive commercial operating rights for Wu Yu Ge globally. Although this layout has imaginative potential, the market is skeptical about its actual implementation, further exacerbating stock price volatility. The U.S. stock market has seen increased volatility recently, and risks should be monitored.
</li>
</ol>
Top Gainers in Pre-Market U.S. Stocks
Healthcare Triangle is up 59.21% in pre-market trading. Based on recent key news:
<ol>
<li>
On February 25, Healthcare Triangle's subsidiary QuantumNexis reached a strategic partnership with TNG Digital in Malaysia to integrate the Ziloy digital mental health platform into the TNG e-wallet. This collaboration aims to provide clinically validated mental health support to over 25 million users, significantly boosting the stock price
Source: Reuters
</li>
<li>
On February 25, Healthcare Triangle detailed the cooperation with TNG Digital in a press release, further enhancing market confidence in the company's future growth. Source: PR Newswire
</li>
<li>
On February 24, Hextar Healthcare Bhd reported a quarterly loss of 31.4 million Malaysian Ringgit. Although there is no direct connection with Healthcare Triangle, it reflects the competitive pressure within the industry. Source: Reuters Industry collaboration drives stock price increase, boosting market confidence.
</li>
</ol>
Curanex Pharmaceuticals pre-market rose 48.53%. Based on recent news,
<ol>
<li>
On February 25, Curanex Pharmaceuticals provided an operational update regarding key regulatory milestones. The company continues to aim for submitting an IND application for ulcerative colitis in the fourth quarter of 2026, which boosted market confidence and significantly drove up the stock price.
</li>
<li>
On February 26, Benzinga's stock rankings indicated that Curanex's price trends were negative across all time frames. However, despite this, the market reacted strongly to the company's recent positive news, leading to a significant increase in stock price. The overall performance of the pharmaceutical industry has been strong recently, with investor sentiment high.
</li>
</ol>
MDJM pre-market rose 43.49%. Based on recent key news:
<ol>
<li>
On February 26, short interest in MDJM Ltd increased, indicating a more pessimistic view among investors regarding the stock. According to data from Benzinga Pro, MDJM's short ratio is above the industry average, which may lead to stock price volatility.
</li>
<li>
On February 26, the short ratio of MDJM Ltd increased, although this does not necessarily mean that the stock price will decline in the short term, traders should be aware of the increasing number of shares being shorted.
</li>
<li>
On February 26, peer comparisons showed that MDJM's short interest is higher than its peers, which may affect market confidence in the stock. The market remains vigilant regarding the increase in short interest
</li>
</ol>

LRMR

ANPA

Larimar Therapeutics pre-market down 8.40%; Rich Sparkle pre-market down 8.12%; Healthcare Triangle pre-market up 59.21%; Curanex Pharmaceuticals pre-market up 48.53%; MDJM pre-market up 43.49%

Pre-market hot trades in US stocks: Larimar Therapeutics pre-market down 8.40%; Rich Sparkle pre-market down 8.12%